Company profile
Northwest Biotherapeutics, Inc.
OTC: NWBO · Healthcare · Biotechnology
#842 of 1,418 Healthcare companies by revenue40th-percentile growth
EA Score
40DFH 23DQ 55GM 44SS 73
v0.1 · 65/100 weight · provisional
↑ disclosure history, listing tenure · ↓ operating margin, net margin
Methodology →Revenue TTM
$2.2M
Rev growth YoY (TTM)
+98.6%
Net income (FY)
-$60.2M
Employees
105
as of 2026-08-13
Market cap
$312.2M
as of 2026-08-13
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$1.4M$1.4M2025
Net income-$60.2M-$60.2M2025
Operating income-$59.9M-$59.9M2025
Total assets$81.3M$81.3M2025
Liabilities$128.9M$128.9M2025
Equity-$60.3M-$60.3M2025
Revenue trend
FY2018 – FY2025 · USD
FY18
FY19
FY20
FY21
FY22
FY24
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Northwest Biotherapeutics, Inc.’s revenue?
Northwest Biotherapeutics, Inc. booked $1.4M in FY2025 revenue, contracting 0.3% year over year — about the middle of the pack among Healthcare companies we track, at a -4365.9% net margin.
Peers · Healthcare
Avenue Therapeutics, Inc.25DWinston Pharmaceuticals, Inc.——Vasamed, Inc.——Affymax, Inc.——CannaPharmaRX, Inc.38DOneMedNet Corporation26DNeighbors
Montgomery →Key facts
CEOLinda F. Powers
SectorHealthcare
IndustryBiotechnology
HeadquartersBethesda, MD
ExchangeOTC: NWBO
Employees105
IPO date2001-12-14
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.